Cellectis Yönetim

Yönetim kriter kontrolleri 3/4

Cellectis CEO'su Andre Choulika, Jan1999 tarihinde atandı, in görev süresi 25.83 yıldır. in toplam yıllık tazminatı $ 876.60K olup, şirket hissesi ve opsiyonları dahil olmak üzere 99.8% maaş ve 0.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.02% ine doğrudan sahiptir ve bu hisseler € 1.76M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 7.7 yıldır.

Anahtar bilgiler

Andre Choulika

İcra Kurulu Başkanı

US$876.6k

Toplam tazminat

CEO maaş yüzdesi	99.8%
CEO görev süresi	25.8yrs
CEO sahipliği	1.0%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	7.7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Andre Choulika'un ücretlendirmesi Cellectis'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$84m
Jun 30 2024	n/a	n/a	-US$79m
Mar 31 2024	n/a	n/a	-US$78m
Dec 31 2023	US$877k	US$875k	-US$109m
Sep 30 2023	n/a	n/a	-US$92m
Jun 30 2023	n/a	n/a	-US$97m
Mar 31 2023	n/a	n/a	-US$91m
Dec 31 2022	US$744k	US$744k	-US$91m
Sep 30 2022	n/a	n/a	-US$63m
Jun 30 2022	n/a	n/a	-US$78m
Mar 31 2022	n/a	n/a	-US$99m
Dec 31 2021	US$879k	US$879k	-US$86m
Sep 30 2021	n/a	n/a	-US$129m
Jun 30 2021	n/a	n/a	-US$121m
Mar 31 2021	n/a	n/a	-US$113m
Dec 31 2020	US$1m	US$1m	-US$37m
Sep 30 2020	n/a	n/a	-US$79m
Jun 30 2020	n/a	n/a	-US$66m
Mar 31 2020	n/a	n/a	-US$67m
Dec 31 2019	US$1m	US$1m	-US$102m

Tazminat ve Piyasa: Andre 'ın toplam tazminatı ($USD 876.60K ) UK pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 736.76K ).

Tazminat ve Kazançlar: Andre şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Andre Choulika (59 yo)

25.8yrs

Görev süresi

US$876,597

Tazminat

Dr. Andre Choulika, Ph.D. is the Founder of Cellectis S.A. and has been its Chief Executive Officer since 1999 and served as its Chairman since 2011 until November 5, 2020. He is the Director of Cellectis...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Andre Choulika	Co-Founder	25.8yrs	US$876.60k	1.02% € 1.8m
David j. Sourdive	Deputy CEO	no data	US$557.84k	0.31% € 529.2k
Arthur Stril	Interim Chief Financial Officer	less than a year	Veri yok	0.0086% € 14.8k
Valerie Cros	Principal Financial Officer & Principal Accounting Officer	2.9yrs	Veri yok	Veri yok
Jean Epinat	Chief Technological Officer	no data	Veri yok	Veri yok
Philippe Duchateau	Chief Scientific Officer	12.8yrs	Veri yok	0.043% € 74.7k
Marie-Bleuenn Terrier	General Counsel & Secretary of the Board of Directors	11.8yrs	Veri yok	0.031% € 52.8k
Pascalyne Wilson	Director of Communications	no data	Veri yok	Veri yok
Kyung Nam-Wortman	Executive VP & Chief Human Resources Officer	4yrs	Veri yok	0.012% € 20.1k
Stephan Reynier	Chief Regulatory & Pharmaceutical Compliance Officer	no data	Veri yok	0.020% € 34.1k
Steven Doares	Senior VP of US Manufacturing & Site Head of the Raleigh	4.3yrs	Veri yok	0.012% € 21.6k
Laurent Poirot	Senior Vice President of Immunology	no data	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: 0WA2 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Andre Choulika	Co-Founder	25.8yrs	US$876.60k	1.02% € 1.8m
David j. Sourdive	Deputy CEO	24.8yrs	US$557.84k	0.31% € 529.2k
Jean-Pierre Garnier	Independent Non-Executive Chairman	4yrs	US$97.34k	0% € 0
Laurent Arthaud	Director	13.1yrs	Veri yok	Veri yok
Pierre Bastid	Independent Director	13.1yrs	US$97.34k	0.056% € 96.5k
Rainer Boehm	Independent Director	7.4yrs	US$99.60k	0% € 0
Dietger Niederwieser	Member of Clinical Advisory Board	7.7yrs	Veri yok	Veri yok
Kanti Rai	Member of Clinical Advisory Board	7.8yrs	Veri yok	Veri yok
Catherine Bollard	Member of Clinical Advisory Board	7.7yrs	Veri yok	Veri yok
Ola Landgren	Member of Clinical Advisory Board	7.7yrs	Veri yok	Veri yok
Marcela Maus	Member of Clinical Advisory Board	7.7yrs	Veri yok	Veri yok
Stephan Grupp	Member of Clinical Advisory Board	6.2yrs	Veri yok	Veri yok

7.7yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0WA2 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.7 yıldır).

Cellectis Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Cellectis S.A., Annual General Meeting, Jun 28, 2024

Cellectis Announces Chief Financial Officer Changes

Cellectis S.A. Announces Board Appointments

Less than half of directors are independent

Cellectis S.A., Annual General Meeting, Jun 27, 2023

Insufficient new directors

Recent updates

Cellectis Presents Multiple Strategies to Enhance Car T-Cell Efficacy in Solid Tumors at the SITC Annual Meeting

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$0.32 loss in 3Q 2023)

Cellectis S.A. to Report Q3, 2024 Results on Nov 04, 2024

New major risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.28 loss per share (vs US$0.089 loss in 2Q 2023)

Cibus, Inc. Achieves Positive Initial Field Trial Results for Stacked Gene Editing Herbicide Tolerant Traits in Rice

Cellectis Announces the Publication of A Scientific Article in Nature Communications

New minor risk - Profitability

First quarter 2024 earnings released: EPS: US$0.079 (vs US$0.49 loss in 1Q 2023)

Cellectis S.A. to Report Q1, 2024 Results on May 28, 2024

Cellectis S.A., Annual General Meeting, Jun 28, 2024

New major risk - Shareholder dilution

New minor risk - Share price stability

Cellectis Announces Chief Financial Officer Changes

No longer forecast to breakeven

Full year 2023 earnings released: US$1.92 loss per share (vs US$1.99 loss in FY 2022)

No longer forecast to breakeven

Cellectis S.A. to Report Q1, 2024 Results on May 09, 2024

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Cellectis S.A. Announces Board Appointments

New major risk - Shareholder dilution

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.63 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Cellectis S.A. to Report Q3, 2023 Results on Nov 06, 2023

Less than half of directors are independent

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of A Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase ? Syndrome Type 1 (APDS1)

Second quarter 2023 earnings released: US$0.089 loss per share (vs US$0.42 loss in 2Q 2022)

Cellectis S.A. to Report Q2, 2023 Results on Aug 03, 2023

New minor risk - Share price stability

Cibus Global, Ltd. completed the acquisition of Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cellectis S.A., Annual General Meeting, Jun 27, 2023

Cellectis S.A. Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T- Cells at ASGCT 2023

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on A Novel Treatment Paradigm for Successful Car T Immunotherapy Against Stroma-Rich Solid Tumors

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

No longer forecast to breakeven

Now 21% undervalued after recent price drop

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Insufficient new directors

Cellectis S.A. Announces the Resignation of Alain Godard as a Member of the Board

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Cellectis S.A Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.82 loss in 3Q 2021)

Cellectis to Showcase Clinical Data from Ameli-01 and Preclinical Data from Ucartcs1 At Ash 2022

Cellectis S.A. to Report Q3, 2022 Results on Nov 03, 2022

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Cellectis Appoints Mark Frattini as Chief Medical Officer

Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.88 loss in 2Q 2021)

Cellectis S.A. Announces Executive Changes

Cellectis S.A. Announces U.S. Food and Drug Administration Clear Cellectis’ Investigational New Drug Application to Initiate A Phase 1/2A Clinical Trial of UCART20x22 for Patients

Cellectis S.A. to Report Q2, 2022 Results on Aug 04, 2022

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Cellectis S.A., Annual General Meeting, Jun 28, 2022

Cellectis Presents Research Data on A Novel Immune-Evasive Universal CAR T-Cell At ASGCT

First quarter 2022 earnings released: US$0.70 loss per share (vs US$0.28 loss in 1Q 2021)

Cellectis S.A. to Report Q1, 2022 Results on May 12, 2022

Cellectis S.A. Releases Preclinical Data on Its Product Candidate UCART20x22 At the American Association for Cancer Research Annual Meeting

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Cellectis S.A. to Report Q4, 2021 Results on Mar 03, 2022

Cellectis Appoints Bing C. Wang as Member of its Executive Committee

Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting

Senior Vice President of Technical Operations - Europe Leopold Bertea has left the company

Third quarter 2021 earnings released: US$0.82 loss per share (vs US$0.71 loss in 3Q 2020)